GlaxoSmithKline Names Tony Wood CSO Designate
19 January 2022 - 6:47PM
Dow Jones News
By Ian Walker
GlaxoSmithKline PLC said Wednesday that it has appointed Tony
Wood as chief scientific officer from August, replacing Hal Barron,
who will become nonexecutive director.
The pharmaceutical giant said Mr. Wood will assume full
accountability for research and development on Aug. 1.
Mr. Wood joined the company in 2017 as senior vice president,
medicinal science and technology, and has more than 30 years of
experience in the industry.
Mr. Barron is stepping down from the role as he has been
appointed CEO and board co-chair of Altos Labs.
"Altogether, these changes provide us with a clear pathway for
continued momentum in R&D to deliver our new ambitions for
growth and scale impact for patients," Chief Executive Emma
Walmsley said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
January 19, 2022 02:32 ET (07:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024